Welcome to our dedicated page for 180 Life Sciences news (Ticker: ATNF), a resource for investors and traders seeking the latest updates and insights on 180 Life Sciences stock.
ETHZilla Corporation, formerly 180 Life Sciences Corp. (ATNF), reports developments tied to its transition from a biotechnology and iGaming-focused issuer into a public-company Ethereum treasury vehicle. Recurring updates cover ETH accumulation, treasury financing, convertible notes, private placements, common stock and warrant ticker changes, and the company’s on-chain yield strategy with Electric Capital as external asset manager.
Company news also covers legacy operating matters, including biotechnology intellectual property in areas such as neuroinflammation, fibrosis and post-operative cognitive dysfunction, as well as the Technology Gaming Platform associated with the company’s iGaming strategy. Capital-structure actions, share repurchases, governance changes and strategic updates remain recurring disclosure themes.
180 Life Sciences Corp. (NASDAQ: ATNF) announced a private placement to raise approximately $15.0 million through the sale of 2,500,000 shares of common stock and accompanying warrants. The combined purchase price is $6.00 per share and warrant, with warrants exercisable at $7.50 each for five years. The closing is anticipated on August 23, 2021, pending customary conditions. Maxim Group LLC is the placement agent. The offering is aimed at accredited investors and includes registration rights for resale of the shares.
180 Life Sciences Corp. (NASDAQ: ATNF) announced that Jagdeep Nanchahal, Professor of Hand Surgery, will present a keynote speech on September 9, 2021, at the British Society for Surgery of the Hand meeting. The presentation will cover his research on Dupuytren's disease and potential treatments targeting fibrotic processes. Dr. James Woody, CEO of 180 Life Sciences, expressed enthusiasm for sharing this significant scientific work with experienced clinicians.
180 Life Sciences Corp. (NASDAQ: ATNF), a clinical-stage biotechnology firm, announced that CEO Dr. James Woody and Professor Jagdeep Nanchahal will participate in the BTIG Virtual Biotechnology Conference from August 9-10, 2021. Their fireside chat is scheduled for August 10 at 1:00 PM ET. The conference will feature discussions on the company's innovative drug development targeting inflammatory diseases and fibrosis. A replay will be available for BTIG clients after the event. 180 Life Sciences is focused on addressing significant unmet medical needs in inflammation and pain.
180 Life Sciences Corp. (NASDAQ: ATNF) has selected a lead synthetic CBD analogue for clinical development targeting inflammation and pain. Collaborating with cannabis chemistry pioneer Professor Raphi Mechoulam and Sir Marc Feldmann, the company identified this non-psychoactive compound from numerous CBD derivatives. The analogue shows potential patent protection, strong preclinical efficacy, and scalability for GMP manufacturing. CEO Dr. James Woody expressed optimism for HUM-217's advancement in clinical trials, marking a significant progress in cannabinoid use in medicine.
180 Life Sciences Corp. (NASDAQ: ATNF) has regained compliance with Nasdaq's listing rule 5250(c)(1) after timely filing its annual and quarterly reports. After previous non-compliance notifications due to late filings of the 2020 Form 10-K and Q1 2021 Form 10-Q, the company submitted these documents on July 9 and July 19, 2021, respectively. Nasdaq confirmed compliance on July 19, 2021, indicating the matter is closed. 180 Life Sciences focuses on developing novel drugs targeting inflammatory diseases, leveraging expertise from top universities.
180 Life Sciences Corp. (NASDAQ: ATNF) announced on July 12, 2021, that it regained compliance with Nasdaq Listing Rules 5605(b)(1) and 5605(c)(2) after appointing new independent directors, thereby closing a compliance matter. The company had previously been notified of non-compliance by Nasdaq, which provided a 45-day period to submit a plan. After timely submission and an extension, the appointment of Pamela G. Marrone and Francis Knuettel II allowed the company to meet all requirements for continued listing.
180 Life Sciences Corp. (NASDAQ: ATNF) announced the publication of a review titled “Collagen VI as a driver and disease biomarker in human fibrosis” in the FEBS Journal. The study, authored by researchers from the University of Oxford, highlights the role of microfibrillar collagen VI in fibrotic diseases affecting vital organs. It identifies collagen VI cleavage fragments as potential biomarkers and therapeutic targets for fibrotic conditions. This publication underscores the company's commitment to advancing drug development for inflammatory diseases and fibrosis.
180 Life Sciences Corp. (NASDAQ: ATNF) announced its inclusion in the Russell Microcap® Index, effective June 28, 2021. This membership is expected to enhance the company’s visibility, increase stock liquidity, and broaden its shareholder base as the Russell indexes are widely used benchmarks for investment strategies.
CEO Dr. James Woody highlighted this inclusion as a pivotal validation for the company, aiming to propel long-term shareholder value. The Russell indexes are benchmarked by approximately $10.6 trillion in assets, indicating significant market relevance.
180 Life Sciences Corp. (ATNF) has been granted an extension until July 31, 2021, by Nasdaq to regain compliance with its listing rules after failing to file its 2020 Form 10-K and Q1 2021 Form 10-Q. The company initially received a notification regarding non-compliance on April 16, 2021, and submitted a compliance plan to Nasdaq by the June 15 deadline. The company is currently working to complete and file the overdue reports to maintain its listing on the Nasdaq.
180 Life Sciences Corp. (NASDAQ: ATNF) has appointed Pamela Marrone, PhD, and Frank Knuettel II, MBA, to its Board of Directors, effective upon the earlier of the filing of the 2020 Form 10-K or June 28, 2021. Dr. Marrone brings over 30 years of experience in biotech, including notable success with Marrone Bio Innovations, with a 5-year revenue CAGR of ~30%. Knuettel has over 25 years in management and finance, previously serving in significant roles within cannabis companies. CEO James Woody expressed confidence that their distinct skill sets will enhance shareholder value.